Constitutive activation of the RON gene, known to code for the tyrosine-kinase receptor for Macrophage Stimulating Protein (also known as Scatter Factor 2), has been shown to induce invasive-metastatic phenotype in vitro. As yet, nothing is known about the expression of this novel member of the MET-oncogene family in spontaneously occurring human cancers. Here we report that Ron is expressed at abnormally high levels in about 50% primary breast carcinomas (35/74 patients). Among these, the expression is increased more than 20-fold in 12 cases and the overexpressed protein is constitutively phosphorylated on tyrosine residues. Notably, Ron is only barely detectable in epithelial cells of the mammary gland, and its expression remains unchanged in benign breast lesions (including adenomas and papillomas). Overexpression was observed in dierent histotypic variants of carcinomas; it is associated with the disease at any stage and correlates with the post-menopausal status. In breast carcinoma cells grown in vitro, activation of the Ron receptor resulted in proliferation, migration and invasion through reconstituted basement membranes. Altogether, these data suggest a role for the RON gene in progression of human breast carcinomas to the invasive-metastatic phenotype.
Introduction
The RON gene encodes a transmembrane tyrosine kinase which has been identi®ed as the receptor for MSP/SF2 (Macrophage Stimulating Protein/Scatter Factor-2, also known as Hepatocyte Growth FactorLike, HGF-L) (Gaudino et al., 1994; Wang et al., 1994) . In epithelial cells, Scatter Factors induce a distinctive biological response that involves cytoskeletal reorganization, loss of intercellular junctions and celldissociation, followed by active migration (Gherardi et al., 1989) . Cell`scattering' is associated with invasion of extracellular matrices (Stoker et al., 1987; Weidner et al., 1990; Giordano et al., 1993) .
RON belongs to the MET oncogene family (Gaudino et al., 1994) : MET, the prototype of the family, codes for the receptor for HGF/Scatter Factor-1 ; SEA, another member of the family, encodes an orphan tyrosine kinase receptor (Hu et al., 1993) . The strong homology between the members of this family is based on structural and biochemical features: (a) the a-b-heterodimeric structure (Giordano et al., 1989; Gaudino et al., 1994) ; (b) two neighboring phospho-tyrosine residues in the kinase domain responsible for up-regulation of the catalytic activity (Ferracini et al., 1991) ; (c) a twotyrosine multifunctional docking site in the C-terminal tail endowed with the uncommon property of concomitantly activating multiple SH2-containing intracellular signal transducers (Ponzetto et al., 1994) . In the Met receptor, phosphorylation of these two tyrosines triggers the intracellular signaling cascade eliciting the distinctive biological response leading to growth,`scattering', morphogenesis in physiological conditions (Montesano et al., 1991; Medico et al., 1996) and to invasive growth in cancer cells in vitro (Giordano et al., 1993; Rong et al., 1994) . Recently, missense mutations located in the tyrosine kinase domain of the MET gene have been identi®ed in the germline of aected members of hereditary papillary renal carcinoma families and in a subset of patients aected by sporadic renal carcinomas of the same histotype. These are likely to be gain-of-function mutations which lead to constitutive activation of the Met protein and to tumorigenesis in renal tissue (Schmidt et al., 1997) .
The RON gene is expressed in a number of epithelial cells, in lineages of hematopoietic origin (such as granulocytes and monocytes) in cells of neuroectodermal origin and in osteoclasts (Gaudino et al., 1994 (Gaudino et al., , 1995 Kurihara et al., 1996) . In liver progenitor cells grown in vitro, Ron activation results in`scattering', invasion of the extracellular matrix and formation of tubular duct-like structures (Medico et al., 1996) . So far, nothing is known about a possible oncogenic potential of the RON gene in human pathology. Constitutive activation of the Ron kinase (obtained by replacement of the Ron extracellular domain with a protein dimerization motif) induces a motile-invasive phenotype, characterized by constitutive cell dissociation,`scattering', invasion of extracellular matrices and formation of aberrant tubular structures in vitro . Moreover, a naturally occurring Ron protein variant, constitutively activated in a gastric carcinoma line, was found to be responsible for the acquisition of invasive properties in vitro. This variant is an uncleaved single-chain protein which undergoes disul®de-linked intracellular dimerization .
At present, no information is available on a possible role of RON in spontaneously occurring human cancers. In this study we focus on human breast carcinomas, as the biological responses controlled by the RON gene namely growth, invasion and induction of tubular structures, may very well explain some biological features of these tumors. We found that the Ron receptor is overexpressed in a signi®cant proportion of carcinomas and that its activation in vitro mediates proliferation, motility and matrix invasion of breast cancer cells.
Results
Expression of the Ron receptor in normal mammary gland, benign lesions and malignant breast tumors A total of 94 breast tissue specimens of the following categories were examined for the Ron receptor expression: (a) normal mammary glands (n=8); (b) benign lesions (n=12); (c) primary ductal or lobular carcinomas (n=74). The Ron protein (p150b
RON
) was barely detectable in the normal mammary gland tissue and in benign lesions including ®broadenomas, papillomas and tissues with microcalci®cations ( Figure 1a and b) . Interestingly, in primary breast carcinomas the Ron receptor was expressed at higher levels than in benign lesions in 35 out of 74 cases, accounting for 47% of the total (Figure 1c ). In the majority of these tumors (23 cases, 31% of the total) the level of expression was increased from 2 ± 20-fold as compared to the amount of protein detectable in benign epithelium. In 12 cases (16% of the patients examined) carcinoma cells overexpressed the Ron protein with an impressive increase of more than 20-fold. A single patient showed a breast carcinoma overexpressing Ron more than 70-fold ( Figure 1c , case 74), determined by densitometric analysis of serial dilution of samples in Western blots (data not shown). To exclude the possibility that dierent amounts of Ron protein merely re¯ected the relative number of epithelial cells in the samples, these data were normalized to the content of K19 cytokeratin marker.
Immunohistochemical analyses performed on selected paran-embedded tumor specimens demonstrated that the Ron receptor is localized on tumor cells. Figure 2 illustrates representative results and shows intense staining of epithelial both in ductal and lobular carcinomas. In all cases the stroma and endothelial cells were not stained.
To investigate the possibility that elevated expression of p150b RON leads to its enzymatic activation in human breast carcinoma, we analysed phosphotyrosine-containing proteins in primary tumors in relationship to Ron expression. As shown in Figure 3 , we found a strong correlation between elevated expression of p150b RON and its phosphorylation. To investigate whether the overexpression of Ron receptor observed in breast carcinomas was due to ampli®cation or to genomic rearrangements, Southern blot analysis was performed. The resulting restriction pattern and hybridization intensities gave no evidence of rearrangements or ampli®cation (data not shown).
The primary breast carcinomas examined were further classi®ed according to their histological and clinical features (see Materials and methods). Clinicopathological parameters were related to the level of Ron receptor expression. Ron overexpressors belonged to dierent histotypic variants. The relatively small number of cases (74 primary carcinomas) did not allow to establish signi®cant links between Ron overexpression and estrogen or progesterone receptors, erbB2 and p53 expression (data not shown). However, a signi®cant correlation was found between Ron overexpression and the post-menopausal status of the patients (Figure 4 ).
Activation of the Ron receptor induces an invasive phenotype in breast cancer cells in vitro
Expression of the Ron receptor was examined in dierent human breast cancer cell lines. The receptor was transcribed and expressed in all the ®ve tumorigenic cell lines analysed (data not shown). ZR75.1 cells ± showing levels of Ron expression comparable to levels found in human tumor samples ± were used as model to study the biochemical and biological responses of cancer cells to MSP/SF2. In these cells the kinase was functionally active, as MSP/ SF2 stimulation triggered tyrosine phosphorylation (Figure 5a ). Nanomolar concentrations of MSP/SF2 induced proliferation after 4 h (Figure 5b ). The motogenic response was studied in a chemotactic assay by seeding cells in the upper chamber of a Transwell plate in which the ligand was added to the lower chamber, as previously described . MSP/SF2 was found to stimulate cell migration and behaves as a strong chemo-attractant (Figure 5c ). The mitogenic and motogenic responses were simultaneously evaluated in a wound healing assay, which tests the ability of ®lling arti®cial gaps created in cell monolayers (Bussolino et al., 1992) . ZR75.1 cells responded to MSP/SF2 and completely repaired the wound in 72 h (Figure 5d ). The invasivemetastatic phenotype was assessed in vitro by a chemoinvasion assay performed using Transwell chambers coated with a reconstituted basement membrane containing collagen IV, laminin and glycosaminoglycans (Kobayashi et al., 1992) . As shown in Figure 5d , ZR75.1 cells invaded and crossed the basement membrane migrating towards the ligand gradient determined by the presence of MSP/SF2 in the lower compartment.
Discussion
Breast cancer is a slow-growing tumor characterized by a long pre-clinical period. Cancerous cells from intraductal lesions suddenly acquire the capacity to invade the surrounding stroma. The molecular mechanism underlying the acquisition of the invasive phenotype is still largely unknown. Genetic alterations that accumulate in breast cancer, including those of the (Kovach et al., 1996; Hartmann et al., 1997) .
Other abnormalities occur in dominant oncogenes, such as those encoding tyrosine kinase receptors. The expression of various members of the EGFR family, namely EGFR, ERBB-2 and ERBB-3 has been found overexpressed in a signi®cant percentage (20 ± 40%) of breast carcinomas (Sainsbury et al., 1985; Fox et al., 1994; Slamon et al., 1987) and in the case of EGFR and ERBB-2 this expression correlates with poor prognosis (Toi et al., 1994; Slamon et al., 1987) . However, both TP53 mutation and overexpression of the EGFR family members have been mostly related to loss of growth control rather than cell invasive behavior, which still needs further study. RON belongs to a tyrosine kinase gene family whose prototype is MET. A number of reports suggest that members of this family are involved in the progression of cancer: (I) germline and somatic missense mutations in the tyrosine kinase domain of MET are involved in papillary renal carcinogenesis (Schmidt et al., 1997) ; (II) Met is overexpressed in some carcinoma types at advanced stages (Di Renzo et al., 1995) ; (III) activation of the Met receptor via an experimental autocrine circuit (Rong et al., 1994) or by rearrangement (Giordano et al., 1997) confers metastatic properties; (IV) all the known members of the family stimulate invasion in vitro (Giordano et al., 1993; Medico et al., 1996) ; (V) although no transforming counterpart of the RON gene has been identi®ed so far, constitutive activation of the Ron kinase elicits a motogenic-invasive phenotype Santoro et al., 1996) .
In the present study we show, for the ®rst time, that the RON gene is associated with a human cancer. The Ron protein, barely detectable in normal breast epithelium and in benign lesions (from calci®cations to non-invasive breast tumors), is overexpressed in a signi®cant percentage of in®ltrating carcinomas.
This aberrant expression may be due to amplification or structural alteration of the gene. To assess whether an amplicon was present in the DNA, we analysed the genomic region where RON and MSP/ SF2 are located: the short arm of chromosome 3 (locus 3p21, Ronsin et al., 1993; Han et al., 1991) . We did not ®nd any ampli®cation in this region. This data suggests that overexpression is controlled at transcriptional level. Interestingly, the RON promoter contains dierent putative binding sites for members of the Ets transcription factor family, which have been associated with the induction of the invasive-metastatic phenotype (Wernert et al., 1994) and are known to be powerful inducers of MET expression (Gambarotta et al., 1996) . This suggests that, in cancer cells, genes of the MET family might be deregulated by a similar transcriptional mechanism.
From a clinical point of view, tumors overexpressing RON were detected in a signi®cant number of postmenopausal patients. This information is puzzling as Ron expression does not relate to the steroid hormone receptor status of tumors and no canonical Steroid Receptor Elements have been found in the RON promoter (Del Gatto et al., 1995) . Although the mechanism is still unknown, this clinical correlation suggests that RON gene overexpression contributes to the development of tumors in a subset of patients.
A number of studies have demonstrated that the protein tyrosine kinase activity might be signi®cantly higher in most malignant human breast cancers than that in normal tissue or in benign tumors (Hennipman et al., 1989) . Here we show that the overexpression of the Ron receptor in human breast cancers is accompanied by its phosphorylation. Ron autophosphorylation could result from clustering and consequent intermolecular interactions of p150b RON monomers, concentrated at high densities at the plasma membrane, or from binding of its own ligand (MSP/SF2) to the external domain of the receptor. Currently no information is available on the involvement in carcinogenesis of this factor. MSP/SF2 might act in a paracrine fashion or via an autocrine mechanism, as demonstrated for the Met/HGF complex in human and murine mammary cancer cells (Tuck et al., 1996; Rahimi et al., 1996) .
Whatever the mechanism is, our results provide evidence that the overexpressed Ron receptor is functionally active in primary breast cancer. The possible biological role of the RON gene in the progression toward malignancy of breast cancer cells was analysed in vitro. In the model cell line ZR75.1, the Ron receptor is functionally active as it is phosphorylated upon the addition of its speci®c ligand and transduces signals which elicit cell growth, motility, migration and invasiveness. Altogether these results suggest that this receptor might confer to breast cancer cells selective properties to move and invade the basement membrane after stimulation by MSP/SF2.
We found that RON is expressed at high levels in the majority of the human breast cancer cell lines analysed. Interestingly, in these cell lines the expression of Ron inversely correlates with the expression of Met (Stoker et al., 1987; Byers et al., 1994) . The data suggesting a role for Met/HGF complex in breast cancer progression are con¯icting (Yamashita et al., 1994; Nagy et al., 1995; Lin et al., 1996; Tuck et al., 1996) . Here, we show that another member of the MET family, with similar biological properties, is overexpressed in a large percentage of breast carcinomas. This observation, together with the demonstration that Ron receptor mediates invasiveness in breast tumor cells in response to its ligand, led us to speculate that this receptor may have a critical role in the progression of mammary carcinomas.
Materials and methods

Reagents and cell lines
Full length pro-MSP/SF2 cDNA was cloned in the Baculovirus transfer vector pVL1392 (Invitrogen) and transfected into Spodoptera frugiperda cells (Sf9 cells) along with Bsu36 I-digested BacPAK6 viral DNA using Lipofectin method (GIBCO BRL). Conditioned supernatant of Sf9 cells was collected 10 days later and tested for MSP/SF2 activity performing a Ron phosphorylation assay on T47D cells. Single recombinant MSP-Baculovirus plaques were isolated by standard plaque assay. Fifteen single plaques were tested for MSP/SF2 activity as described above and one of them was used to produce the pro-MSP/SF2 required for all the experiments. Recombinant pro-MSP/SF2 was cleaved to the mature form MSP/SF2 by incubation at 378C for 12 h, in the presence of 10% Fetal Calf Serum (FCS). Conditioned medium derived from Sf9 cells infected with an empty pVL1392-BacPAK6 virus added of 10% FCS was used as control in all the experiments described in this work.
Breast cancer cell lines ZR75.1, BT.474, MDA-MB.231, SK-BR.3, MCF.7 were purchased from the ATCC. GTL-16 gastric cancer cell line has been previously characterized (Giordano et al., 1989) . Cells were grown in DMEM supplemented with 10% FCS in a humidi®ed atmosphere with 5% CO 2 .
Tissue samples
Breast tissues were from patients treated at the Department of Gynecologic Oncology of the University of Torino Medical School and Department of Endocrinology of the University of Catania Medical School. Carcinomas (74 cases) were classi®ed as ductal (57) or non-ductal (17). In 67 cases pTNM and Grading were available as follows: T1=29 cases, T2 ± 4=38 cases; G1 ± G2=39 cases, G3=28 cases; ER+=46, ER7=28; PR+=42, PR7=32. Normal breast tissue was obtained from reduction mammoplasty.
Statistics
The correlation of various disease parameters was evaluated using contingency tables analysed by the w 2 test. A P value of 50.05 was considered to be signi®cant. When the sample size was relatively small the Fisher exact test was used to calculate the dierences between groups in contingency tables. Pearson or Spearman correlation coecient were calculated.
Immunoprecipitation and Western blot analysis
Tissue samples, removed at surgery, were treated as previously described (Di Renzo et al., 1994) . The powdered whole tissue was homogenized in TEN buer (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 1% Nonidet P40, 0.5% NaDOC), containing protease inhibitors. Equal amounts of proteins were immunoprecipitated with a rabbit polyclonal antibody raised against the Cterminal tail of human Ron (Gaudino et al., 1994) . SDS ± PAGE, Western blot with streptavidin-HRP and enhanced Chemiluminescence kit (ECL, Amersham) were performed. Under reducing conditions, the 150 KDa b and the 35 KDa a chain which constitute the 185 KDa Ron receptor are separated. The Ron antibody recognizes the b chain and the 170 KDa precursor. Using a RIPA buer only the b chain was detectable. The expression of Ron protein was quanti®ed by laser densitometric scanning of X-ray ®lms and normalized by comparison with the control sample included in each gel (GTL16 extracts). The relative number of epithelial cells in each sample was analysed performing a Western blot on total proteins. Blots were then decorated with a K19 cytokeratin monoclonal antibody (Amersham).
Tyrosine phosphorylation assay
In vivo tyrosine phosphorylation of breast tissues and cells was evaluated by Ron immunoprecipitation and Western blot analysis using phosphotyrosine monoclonal antibodies (UBI). Tumor tissues were snap frozen in liquid N 2 immediately after surgery and stored at 7708C for a maximum of 3 weeks, in order to maintain the phosphorylation state of the proteins. Subcon¯uent ZR75.1 cells were treated or untreated with recombinant MSP/SF2, for 10 min at 378C. Tissues and cells were lysed in TEN buer containing 100 mM Na 3 VO 4 and protease inhibitors. Immunoprecipitation was performed as described above.
Immunohistochemistry
Surgical specimens were ®xed and paran embedded by standard procedures. Four mm sections from wax tissue blocks were deparanized and immersed in a 0.1% hydrogen peroxide-methanol solution to block the endogenous peroxidase activity. Sections were covered overnight at room temperature with Ron polyclonal antibody (Santa Cruz), followed by incubation with avidin-biotin-peroxidase complex (ABC, Vector Labs) for 30 min at room temperature. After incubation with a solution of 0.01% diaminobenzidine and hydrogen peroxide for 5 min, the sections were lightly counterstained with haematoxylin.
Biological assays
Cell proliferation was tested as follows: 1.5610 5 cells/ 20 mm culture dish were plated in DMEM 10% FCS for 24 h, added of MSP/SF2 (300 ng/ml) in DMEM 3% FCS and counted after 4, 24 and 48 h.
For the wound healing assay 1.5610 6 cells were seeded into 35 mm plate wells and grown for 48 h. A wound was made with a plastic pipette tip in a con¯uent monolayer of cells. Cells were then incubated for 72 h in the presence of DMEM 3% FCS, with or without MSP/SF2 at the above concentrations, ®xed with glutaraldehyde and stained with crystal violet. Images of cell samples were taken by a computer assisted telecamera.
The assays for cell motility and matrix invasion were performed in Transwell 1 chambers (Costar Corporation). Brie¯y, 10 5 cells seeded on the upper side of a porous polycarbonate membrane (8.07mm7pore size) coated (invasion assay) or not coated (cell migration assay) with the arti®cial basement membrane Matrigel 1 (12.5 mg per ®lter; Collaborative Biomedical Products; Becton Dickinson Labware). MSP/SF2 at the above concentrations was added to the lower compartment. Only cells able to migrate or with an invasive phenotype, move through the membrane and grow on the lower side of the ®lter. After 24 h of incubation (for migration assays) or 72 h (for invasion assays), cells attached to the upper side of the ®lters were mechanically removed, whilst cells that migrated or invaded the Matrigel 1 were ®xed and stained as previously described (Medico et al., 1996) . Cells were counted (migration assay) or cells were photographed by a computer assisted telecamera (invasion assay). Both assays were performed in the presence of low serum concentration (3% FCS). help in elaborating statistical data. We thank R Albano, R Callipo, L Palmas, G Petrucelli and M Milano for their technical assistance. The secretarial help of Miss A Cignetto and text editing by E Wright are gratefully acknowledged. This work was supported by grants from the Italian National Research Council (CNR ± Progetto Finalizzato ACRO no. 96.00556.PF39 to MFD and no. 96.00543.PF39 to PMC) and of the Associazione Italiana per la Ricerca sul Cancro (AIRC).
